JP4845379B2 - サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン - Google Patents

サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン Download PDF

Info

Publication number
JP4845379B2
JP4845379B2 JP2004538237A JP2004538237A JP4845379B2 JP 4845379 B2 JP4845379 B2 JP 4845379B2 JP 2004538237 A JP2004538237 A JP 2004538237A JP 2004538237 A JP2004538237 A JP 2004538237A JP 4845379 B2 JP4845379 B2 JP 4845379B2
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
cycloalkyl
moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004538237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507254A5 (https=
JP2006507254A (ja
Inventor
マイケル ピー． ドワイヤー，
ティモシー ジェイ． グジ，
カミル パルチ，
ロナルド ジェイ． ドール，
カルティック エム． キールティカー，
ヴィヨール エム． ギリジャバルラブハン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006507254A publication Critical patent/JP2006507254A/ja
Publication of JP2006507254A5 publication Critical patent/JP2006507254A5/ja
Application granted granted Critical
Publication of JP4845379B2 publication Critical patent/JP4845379B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004538237A 2002-09-19 2003-09-17 サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン Expired - Fee Related JP4845379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41206302P 2002-09-19 2002-09-19
US60/412,063 2002-09-19
PCT/US2003/029498 WO2004026867A2 (en) 2002-09-19 2003-09-17 Imidazopyridines as cyclin dependent kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2006507254A JP2006507254A (ja) 2006-03-02
JP2006507254A5 JP2006507254A5 (https=) 2006-10-05
JP4845379B2 true JP4845379B2 (ja) 2011-12-28

Family

ID=32030794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538237A Expired - Fee Related JP4845379B2 (ja) 2002-09-19 2003-09-17 サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン

Country Status (18)

Country Link
US (2) US6992080B2 (https=)
EP (1) EP1539756B1 (https=)
JP (1) JP4845379B2 (https=)
KR (1) KR20050052500A (https=)
CN (1) CN100549011C (https=)
AR (1) AR041291A1 (https=)
AT (1) ATE378336T1 (https=)
AU (1) AU2003295332B2 (https=)
CA (1) CA2499639C (https=)
DE (1) DE60317529T2 (https=)
ES (1) ES2293068T3 (https=)
IL (1) IL167433A (https=)
MX (1) MXPA05003058A (https=)
MY (1) MY133311A (https=)
NZ (1) NZ538566A (https=)
TW (1) TWI351405B (https=)
WO (1) WO2004026867A2 (https=)
ZA (1) ZA200502278B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
GB9819530D0 (en) 1998-09-09 1998-10-28 Smithkline Beecham Plc Novel compositions and use
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CN101146532B (zh) * 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
WO2006100119A1 (en) * 2005-03-24 2006-09-28 Glaxo Group Limited Derivatives of imidazo (1,2-a) pyridine useful as medicaments for treating gastrointestinal diseases
JP2009507843A (ja) 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
JP2010511019A (ja) * 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
JP5643105B2 (ja) * 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
JP5421925B2 (ja) * 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CN102131805A (zh) * 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
WO2010006947A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
TW201018682A (en) * 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
PL2716157T3 (pl) 2008-12-08 2017-06-30 Gilead Connecticut, Inc. Imidazopirazynowe inhibitory Syk
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
WO2012136531A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
PE20160605A1 (es) 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
KR20160090903A (ko) 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
HK1254892A1 (zh) 2016-01-14 2019-08-02 韩德株式会社 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
TW201841916A (zh) * 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
EP4593958A1 (en) * 2022-09-28 2025-08-06 Origenis GmbH Novel cdk9 inhibitors
CN121866256A (zh) * 2023-09-15 2026-04-14 株式会社汇恩斯 用于预防、减轻或治疗胃肠炎性疾病或胃酸相关疾病的新的基于咪唑并吡啶的化合物和包含其作为活性成分的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011000A2 (en) * 1998-08-21 2000-03-02 Astrazeneca Ab New compounds
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
WO2002069968A1 (en) * 2001-03-08 2002-09-12 Astrazeneca Ab New use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
WO1995007276A1 (en) 1993-09-10 1995-03-16 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
JPH11505524A (ja) * 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
JP4007743B2 (ja) * 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
SE0003186D0 (sv) 2000-09-07 2000-09-07 Astrazeneca Ab New process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011000A2 (en) * 1998-08-21 2000-03-02 Astrazeneca Ab New compounds
WO2001056607A1 (en) * 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
WO2002069968A1 (en) * 2001-03-08 2002-09-12 Astrazeneca Ab New use

Also Published As

Publication number Publication date
AU2003295332B2 (en) 2007-01-18
US6992080B2 (en) 2006-01-31
CN100549011C (zh) 2009-10-14
WO2004026867A3 (en) 2004-08-05
IL167433A (en) 2011-03-31
MXPA05003058A (es) 2005-05-27
TWI351405B (en) 2011-11-01
ATE378336T1 (de) 2007-11-15
WO2004026867A2 (en) 2004-04-01
TW200407322A (en) 2004-05-16
NZ538566A (en) 2008-02-29
KR20050052500A (ko) 2005-06-02
ZA200502278B (en) 2006-05-31
EP1539756B1 (en) 2007-11-14
US20040097517A1 (en) 2004-05-20
AR041291A1 (es) 2005-05-11
MY133311A (en) 2007-11-30
AU2003295332A1 (en) 2004-04-08
DE60317529T2 (de) 2008-09-25
JP2006507254A (ja) 2006-03-02
CA2499639C (en) 2011-11-08
HK1071757A1 (en) 2005-07-29
US7452902B2 (en) 2008-11-18
ES2293068T3 (es) 2008-03-16
US20060030555A1 (en) 2006-02-09
EP1539756A2 (en) 2005-06-15
DE60317529D1 (de) 2007-12-27
CA2499639A1 (en) 2004-04-01
CN1703414A (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
JP4571969B2 (ja) キナーゼインヒビターとしてのピラゾロトリアジン
JP4790265B2 (ja) サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP4799864B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
JP4700344B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP4881558B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006502184A5 (https=)
JP2006503838A (ja) サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
JP2006501260A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2009511483A (ja) 癌の処置のためのサイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2011074088A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP4845380B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2009511477A (ja) サイクリン依存性キナーゼインヒビターとしての、新規なピラゾロピリミジン
JP2009507843A (ja) アザ縮合サイクリン依存性キナーゼ阻害剤
JP2010180234A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111011

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees